Multiple studies are investigating the use of somatostatin antagonists with Lu177 radionucleotides that are internalized by the receptor-positive tumors cells and causes DNA damage resulting in cytotoxicity in other SSTR-positive tumors such as neuroendocrine tumors (76). Here, SST is linked to neuroendocrine neoplasm.